- 基本信息
导师姓名:
|
李福彬
|
学科代码:
|
100100
|
|
性别:
|
男
|
学科名称:
|
基础医学
|
培养单位:
|
基础医学院
|
三级学科
|
|
导师类型:
|
博士生导师
|
专业领域名称:
|
|
联系方式:
|
李福彬,博士,研究员,课题组长,上海市免疫学研究所,上海交通大学医学院基础医学院免疫学与微生物学系,上海市重庆南路280号西区5号楼1008室,邮编200025;邮箱: Fubin.Li@sjtu.edu.cn,电话:021-54592183(办公室)
Fubin Li, Ph.D,Principal Investigator, Shanghai Institute of Immunology; Department of Immunology and Microbiology, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine
Room 1008, West #5 Building, 280 South Chongqing Road, Shanghai 200025, China;Email: Fubin.Li@sjtu.edu.cn;Phone: +86-21-54592183 (office)
|
专业领域代码:
|
|
邮编:
|
200025
|
邮箱地址:
|
Fubin.Li@sjtu.edu.cn
|
- 研究方向 (点击浏览详细信息)
- 社会任职
- 科研项目
19431902900 | 新型激动型抗肿瘤抗CD40抗体的临床前研究 | 上海市科技委员会 |
2019-04~2022-03
|
60万元
| 课题负责人 |
横向课题 | 横向课题 | 生物科技企业 |
2019-03~2021-03
|
60万元
| 课题负责人 |
31870924 | IgG亚型对落叶型天疱疮Dsg1自身抗体致病性的影响及机制 | 国家自然科学基金面上项目 |
2019-01~2022-12
|
60万元
| 课题负责人 |
3181101056 | 通过单克隆抗体靶向干预TIGIT-PVR联系进行肿瘤免疫治疗:Fc受体的影响 | 国家自然科学基金国际(地区)合作与交流项目(中以) |
2019-01~2021-12
|
160万元
| 课题负责人 |
18140902600 | 单克隆抗体靶点和受体多基因人源化小鼠模型的开发和应用 | 上海科学技术委员会 |
2018-05~2021-04
|
30万元
| 课题负责人 |
横向课题 | 横向课题 | 生物科技企业 |
2018-05~2019-08
|
85万元
| 课题负责人 |
2018ZX10302301-002 | 基于新型结核抗原特异性免疫应答的诊断策略与产品研发 | 科技部重点专项 |
2018-01~2020-12
|
408万元
| 子课题负责人 |
国家高层次人才计划 | 国家高层次人才计划青年项目 | 国家 |
2015-01~2018-12
|
200万元
| 课题负责人 |
31422020 | 基于抗体Fc的分子靶向治疗 | 国家自然科学基金委员会优青项目 |
2015-01~2017-12
|
100万元
| 课题负责人 |
31370934 | 抑制型Fcgamma受体驱动激动型抗TNFR超家族成员抗体抗肿瘤活性的机制 | 国家自然科学基金委员会面上项目 |
2014-01~2017-12
|
80万元
| 课题负责人 |
2014CB943600 | 淋巴细胞发育中的基因转录后调节网络研究 | 中华人民共和国科学技术部 |
2014-01~2018-08
|
150万元
| 课题参与人 |
上海市教委人才项目 | 上海市教委项目 | 上海市教育委员会 |
2013-09~2016-08
|
100万元
| 课题负责人 |
- 学术论文
Xiaobo Liu*, Yingjie Zhao*, Huan Shi*, Yan Zhang, Xueying Yin, Mingdong Liu, Huihui Zhang, Yongning He, Boxun Lu, Tengchuan Jin,
|
Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
|
Nature Communications
|
2019
|
in press
|
Wenqian Zhang*, Huihui Zhang*, Shujun Liu, Fucan Xia, Zijian Kang, Yan Zhang, Yaoyang Liu, Hui Xiao, Lei Chen, Chuanxin Huang, Nan Shen, Huji Xu,
|
Excessive CD11c+Tbet+ B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus.
|
Proc Natl Acad Sci U S A
|
2019
|
first published August 26, 2019
|
Li M*, Lazorchak AS*, Ouyang X, Zhang H, Liu H, Arojo OA, Yan L, Jin J, Han Y, Qu G, Fu Y, Xu X, Liu X, Zhang W, Yang Z, Ruan C, Wang Q, Liu D, Huang C, Lu L, Jiang S, Li,, Su, B#
|
Sin1/mTORC2 regulates B cell growth and metabolism via mTORC1 and Myc activation
|
Cellular & Molecular Immunology
|
2019
|
2019 Jan 31
|
Dahan R, Barnhart BC,, Yamniuk AP, Korman AJ, Ravetch JV.
|
Therapeutic activity of agonistic, human anti-CD40 monoclonal Abs requires selective FcγR-engagement
|
Cancer Cell
|
2016
|
29(6):820-31
|
Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, ?stling J, Dahan R, Harris RA, Rantalainen M, Klevebring D, Sund M, Brage SE, Fuxe J, Rolny C,, Ravetch JV, Karlsson MC.
|
Reprogramming tumor associated macrophages by antibody targeting inhibits cancer progression and metastasis.
|
Cell Reports
|
2016
|
15(9):2000-11
|
Deng Z, Ma S, Zhou H, Zang A, Fang Y, Li T, Shi H, Liu M, Du M, Taylor PR, Zhu HH, Chen J, Meng G,, Chen C, Zhang Y, Jia XM, Lin X, Zhang X, Pearlman E, Li X, Feng GS, Xiao H.
|
Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal TH17 responses.
|
Nature Immunology
|
2015
|
16(6):642-52
|
, F., P. Smith, and J. V. Ravetch. 2014.
|
Inhibitory Fcgamma Receptor Is Required for the Maintenance of Tolerance through Distinct Mechanisms.
|
Journal of Immunology
|
2014
|
192(7):3021-8.
|
, Ravetch JV.
|
Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo
|
Proc Natl Acad Sci U S A
|
2013
|
110(48):19501-6
|
Simpson TR,, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA.
|
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
|
J Exp Med
|
2013
|
210(9):1695-710
|
Smith P, DiLillo DJ, Bournazos S,, Ravetch JV.
|
Mouse model recapitulating human Fcγ receptor structural & functional diversity
|
Proc Natl Acad Sci U S A
|
2012
|
109(16):6181-6
|
, Ravetch JV.
|
A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies
|
Cell Cycle
|
2012
|
11(18):3343-4
|
, Ravetch JV.
|
Apoptotic & antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.
|
Proc Natl Acad Sci U S A
|
2012
|
109(27):10966-71
|
, Ravetch JV.
|
Inhibitory Fcγ receptor engagement drives adjuvant & anti-tumor activities of agonistic CD40 antibodies.
|
Science
|
2011
|
333(6045):1030-4
|
, Yan Y, Pieretti J, Feldman DA, Eckhardt LA.
|
Comparison of identical & functional Igh alleles reveals a nonessential role for Eμ in somatic hypermutation & class-switch recombination.
|
J Immunol
|
2010
|
185(10):6049-57
|
, Eckhardt LA.
|
A role for the IgH intronic enhancer E mu in enforcing allelic exclusion.
|
J Exp Med
|
2009
|
206(1):153-67
|
Zhang B, Alaie-Petrillo A, Kon M,, Eckhardt LA.
|
Transcription of a productively rearranged Ig VDJC alpha does not require the presence of HS4 in the IgH 3' regulatory region.
|
J Immunol
|
2007
|
178(10):6297-306
|
Romov PA,, Lipke PN, Epstein SL, Qiu WG.
|
Comparative genomics reveals long, evolutionarily conserved, low-complexity islands in yeast proteins.
|
J Mol Evol
|
2006
|
63(3):415-25
|
Garrett FE, Emelyanov AV, Sepulveda MA, Flanagan P, Volpi S,, Loukinov D, Eckhardt LA, Lobanenkov VV, Birshtein BK.
|
Chromatin architecture near a potential 3' end of the igh locus involves modular regulation of histone modifications during B-Cell development & in vivo occupancy at CTCF sites.
|
Mol Cell Biol
|
2005
|
25(4):1511-25.
|
|